keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/28301631/androgen-receptor-function-and-androgen-receptor-targeted-therapies-in-breast-cancer-a-review
#1
Miho Kono, Takeo Fujii, Bora Lim, Meghan Sri Karuturi, Debasish Tripathy, Naoto T Ueno
Importance: The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. To date, AR-targeted drugs have been approved only for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation. Through review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-related pathways, the potential for AR-targeted therapies in breast cancer, and potential biomarkers for AR-targeted treatments...
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28295408/circulating-tumor-cells-as-a-marker-for-progression-free-survival-in-metastatic-castration-na%C3%A3-ve-prostate-cancer
#2
Andreas Josefsson, Anna Linder, Despina Flondell Site, Giacomo Canesin, Anna Stiehm, Aseem Anand, Anders Bjartell, Jan-Erik Damber, Karin Welén
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study...
March 10, 2017: Prostate
https://www.readbyqxmd.com/read/28285791/immunohistochemical-study-of-the-neural-development-transcription-factors-ttf1-ascl1-and-brn2-in-neuroendocrine-prostate-tumours
#3
E Rodríguez-Zarco, A Vallejo-Benítez, S Umbría-Jiménez, S Pereira-Gallardo, S Pabón-Carrasco, A Azueta, R González-Cámpora, P S Espinal, A García-Escudero
OBJECTIVE: Prostatic small-cell neuroendocrine carcinoma is an uncommon malignancy that constitutes 0.5-1% of all prostate malignancies. The median cancer-specific survival of patients with prostatic small-cell neuroendocrine carcinoma is 19 months, and 60.5% of the patients have metastatic disease. Neural development transcription factors are molecules involved in the organogenesis of the central nervous system and of neuroendocrine precursors of various tissues, including the suprarenal gland, thyroid glands, lungs and prostate...
March 9, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28272687/prognostic-value-of-twist-1-e-cadherin-and-ezh2-in-prostate-cancer-an-immunohistochemical-study
#4
Aziza E Abdelrahman, Shimaa A Arafa, Ragab A Ahmed
OBJECTIVE: There is an urgent need to identify molecular biomarkers rather than clinical markers to distinguish aggressive prostate cancer from the indolent majority for proper treatment and accurate prediction of prognosis. We aimed to investigate the immunohistochemical expression of epithelial-mesenchymal transition (EMT)-related molecules (Twist-1 and E-cadherin) and the stem cell marker EZH2 in prostate cancer and to assess their ability to identify the high-risk patients, in a trial to explore their prognostic implications...
February 4, 2017: Türk Patoloji Dergisi
https://www.readbyqxmd.com/read/28272467/meta-analysis-identifies-novel-risk-loci-and-yields-systematic-insights-into-the-biology-of-male-pattern-baldness
#5
Stefanie Heilmann-Heimbach, Christine Herold, Lara M Hochfeld, Axel M Hillmer, Dale R Nyholt, Julian Hecker, Asif Javed, Elaine G Y Chew, Sonali Pechlivanis, Dmitriy Drichel, Xiu Ting Heng, Ricardo C-H Del Rosario, Heide L Fier, Ralf Paus, Rico Rueedi, Tessel E Galesloot, Susanne Moebus, Thomas Anhalt, Shyam Prabhakar, Rui Li, Stavroula Kanoni, George Papanikolaou, Zoltán Kutalik, Panos Deloukas, Michael P Philpott, Gérard Waeber, Tim D Spector, Peter Vollenweider, Lambertus A L M Kiemeney, George Dedoussis, J Brent Richards, Michael Nothnagel, Nicholas G Martin, Tim Becker, David A Hinds, Markus M Nöthen
Male-pattern baldness (MPB) is a common and highly heritable trait characterized by androgen-dependent, progressive hair loss from the scalp. Here, we carry out the largest GWAS meta-analysis of MPB to date, comprising 10,846 early-onset cases and 11,672 controls from eight independent cohorts. We identify 63 MPB-associated loci (P<5 × 10(-8), METAL) of which 23 have not been reported previously. The 63 loci explain ∼39% of the phenotypic variance in MPB and highlight several plausible candidate genes (FGF5, IRF4, DKK2) and pathways (melatonin signalling, adipogenesis) that are likely to be implicated in the key-pathophysiological features of MPB and may represent promising targets for the development of novel therapeutic options...
March 8, 2017: Nature Communications
https://www.readbyqxmd.com/read/28264535/-clinical-significance-of-neutrophil-to-lymphocyte-ratio-in-patients-with-prostate-cancer
#6
Hirohito Naito, Mikio Sugimoto, Shigeo Taketa, Yoshiyuki Kakehi
Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has clinical and prognostic value in patients with cancer. We evaluated the role of NLR prior to biopsy in patients suspected of having cancer prostate cancer. In this retrospective study, we reviewed the records of 204 patients who underwent prostate biopsy in Mizushima Kyodo Hospital between August 2002 and June 2015 and collected the following data : age, C-reactive protein (CRP), prostate volume (PV), clinical cancer staging, prostate-specific antigen (PSA) prior to biopsy , Gleason score (GS), NLR...
February 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28241827/microrna-30d-promotes-angiogenesis-and-tumor-growth-via-mypt1-c-jun-vegfa-pathway-and-predicts-aggressive-outcome-in-prostate-cancer
#7
Zhuo-Yuan Lin, Guo Chen, Yan-Qiong Zhang, Hui-Chan He, Yu-Xiang Liang, Jian-Heng Ye, Ying-Ke Liang, Ru-Jun Mo, Jian-Ming Lu, Yang-Jia Zhuo, Yu Zheng, Fu-Neng Jiang, Zhao-Dong Han, Shu-Lin Wu, Wei-de Zhong, Chin-Lee Wu
BACKGROUND: Even though aberrant expression of microRNA (miR)-30d has been reported in prostate cancer (PCa), its associations with cancer progression remain contradictory. The aim of this study was to investigate clinical significance, biological functions and underlying mechanisms of miR-30d deregulation in PCa. METHODS: Involvement of miR-30d deregulation in malignant phenotypes of PCa was demonstrated by clinical sample evaluation, and in vitro and in vivo experiments...
February 27, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28235401/expression-of-socs1-and-the-downstream-targets-of-its-putative-tumor-suppressor-functions-in-prostate-cancer
#8
Martin Chevrier, Diwakar Bobbala, Alberto Villalobos-Hernandez, Md Gulam Musawwir Khan, Sheela Ramanathan, Caroline Saucier, Gerardo Ferbeyre, Sameh Geha, Subburaj Ilangumaran
BACKGROUND: Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent epigenetic and micro-RNA-mediated repression of its gene expression in diverse cancers. In prostate cancer (PCa), elevated expression of miR-30d that targets SOCS1 mRNA is associated with increased risk of disease recurrence. SOCS1 can mediate its tumor suppressor functions by diverse mechanisms such as inhibiting the JAK-STAT signaling pathway, promoting the tumor suppressor functions of p53, attenuating MET receptor tyrosine kinase signaling and blocking the oncogenic potential of the cell cycle inhibitor p21(CIP1) (p21)...
February 24, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28222672/long-leukocyte-telomere-length-in-prostate-cancer-patients-at-diagnosis-is-associated-with-poor-metastasis-free-and-cancer-specific-survival
#9
Ulrika Svenson, Göran Roos, Pernilla Wikström
Previous studies have suggested that leukocyte telomere length is associated with risk of developing prostate cancer. Investigations of leukocyte telomere length as a prognostic factor in prostate cancer are, however, lacking. In this study, leukocyte telomere length was investigated both as a risk marker, comparing control subjects and patient risk groups (based on serum levels of prostate-specific antigen, tumor differentiation, and tumor stage), and as a prognostic marker for metastasis-free and cancer-specific survival...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28192399/c-met-mir-130b-axis-as-novel-mechanism-and-biomarker-for-castration-resistance-state-acquisition
#10
A Cannistraci, G Federici, A Addario, A L Di Pace, L Grassi, G Muto, D Collura, M Signore, L De Salvo, S Sentinelli, G Simone, M Costantini, S Nanni, A Farsetti, V Coppola, R De Maria, D Bonci
Although a significant subset of prostate tumors remain indolent during the entire life, the advanced forms are still one of the leading cause of cancer-related death. There are not reliable markers distinguishing indolent from aggressive forms. Here we highlighted a new molecular circuitry involving microRNA and coding genes promoting cancer progression and castration resistance. Our preclinical and clinical data demonstrated that c-Met activation increases miR-130b levels, inhibits androgen receptor expression, promotes cancer spreading and resistance to hormone ablation therapy...
February 13, 2017: Oncogene
https://www.readbyqxmd.com/read/28187449/low-pca3-expression-is-a-marker-of-poor-differentiation-in-localized-prostate-tumors-exploratory-analysis-from-12-076-patients
#11
Mohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, Maria Santiago-Jiménez, Nicholas Erho, Jennifer Jordan, Kasra Yousefi, Lucia L C Lam, Tyler Kolisnik, Jijumon Chelissery, Roland Seiler, Ashley E Ross, R Jeffrey Karnes, Edward M Schaeffer, Tamara T Lotan, Robert B Den, Stephen J Freedland, Elai Davicioni, Eric A Klein, Jack A Schalken
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28161841/prognostic-factors-of-first-line-docetaxel-treatment-in-castration-resistant-prostate-cancer-roles-of-neutrophil-to-lymphocyte-ratio-in-patients-from-northwestern-china
#12
Xin-Qi Pei, Da-Lin He, Ge Tian, Wei Lv, Yu-Mei Jiang, Da-Peng Wu, Jin-Hai Fan, Kai-Jie Wu
OBJECTIVE: To evaluate the potential role of neutrophil-to-lymphocyte ratio (NLR) with therapeutic response in patients who were treated with docetaxel for mCRPC. MATERIALS AND METHODS: We retrospectively analyzed the clinical data from 111 consecutive patients who were treated with docetaxel for mCRPC from 2009 to 2016 in a single center from Northwestern China. Pretreatment baseline and follow-up data including age, PSA response, Gleason score, and cycle number were reviewed, and multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival (OS) and progression-free survival (PFS)...
April 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28160568/serum-ferritin-in-combination-with-prostate-specific-antigen-improves-predictive-accuracy-for-prostate-cancer
#13
Xijuan Wang, Peng An, Jiling Zeng, Xiaoyan Liu, Bo Wang, Xuexian Fang, Fudi Wang, Guoping Ren, Junxia Min
Ferritin is highly expressed in many cancer types. Although a few studies have reported an association between high serum ferritin levels and an increased risk of prostate cancer, the results are inconsistent. Therefore, we performed a large case-control study consisting of 2002 prostate cancer patients and 951 control patients with benign prostatic hyperplasia (BPH). We found that high ferritin levels were positively associated with increased serum prostate-specific antigen (PSA) levels and prostate cancer risk; each 100 ng/ml increase in serum ferritin increased the odds ratio (OR) by 1...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28152172/the-abc-model-of-prostate-cancer-a-conceptual-framework-for-the-design-and-interpretation-of-prognostic-studies
#14
REVIEW
Andreas Pettersson, Travis Gerke, Katja Fall, Yudi Pawitan, Lars Holmberg, Edward L Giovannucci, Philip W Kantoff, Hans-Olov Adami, Jennifer R Rider, Lorelei A Mucci
There has been limited success in identifying prognostic biomarkers in prostate cancer. A partial explanation may be that insufficient emphasis has been put on clearly defining what type of marker or patient category a biomarker study aims to identify and how different cohort characteristics affect the ability to identify such a marker. In this article, the authors put forth the ABC model of prostate cancer, which defines 3 groups of patients with localized disease that an investigator may seek to identify: patients who, within a given time frame, will not develop metastases even if untreated (category A), will not develop metastases because of radical treatment (category B), or will develop metastases despite radical treatment (category C)...
February 2, 2017: Cancer
https://www.readbyqxmd.com/read/28146062/high-level-%C3%AE-glutamyl-hydrolase-ggh-expression-is-linked-to-poor-prognosis-in-erg-negative-prostate-cancer
#15
Nathaniel Melling, Masoud Rashed, Cornelia Schroeder, Claudia Hube-Magg, Martina Kluth, Dagmar Lang, Ronald Simon, Christina Möller-Koop, Stefan Steurer, Guido Sauter, Frank Jacobsen, Franziska Büscheck, Corinna Wittmer, Till Clauditz, Till Krech, Maria Christina Tsourlakis, Sarah Minner, Hartwig Huland, Markus Graefen, Lars Budäus, Imke Thederan, Georg Salomon, Thorsten Schlomm, Waldemar Wilczak
γ-glutamyl-hydrolase (GGH) is a ubiquitously-expressed enzyme that regulates intracellular folate metabolism for cell proliferation, DNA synthesis, and repair. Employing GGH immunohistochemistry on a tissue microarray with 12,427 prostate cancers, we found that GGH expression was negative to low in normal prostate epithelium, whereas 88.3% of our 10,562 interpretable cancers showed GGH expression. GGH staining was considered as low intensity in 49.6% and as high intensity in 38.6% of cancers. High GGH expression was linked to the TMPRSS2:ERG-fusion positive subset of cancers (p < 0...
January 29, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28143998/correction-genomic-deletion-of-chromosome-12p-is-an-independent-prognostic-marker-in-prostate-cancer
#16
Martina Kluth, Ramin Ahrary, Claudia Hube-Magg, Malik Ahmed, Heinke Volta, Catina Schwemin, Stefan Steurer, Corinna Wittmer, Waldemar Wilczak, Eike Burandt, Till Krech, Meike Adam, Uwe Michl, Hans Heinzer, Georg Salomon, Markus Graefen, Christina Koop, Sarah Minner, Ronald Simon, Guido Sauter, Thorsten Schlomm
No abstract text is available yet for this article.
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28134773/wisteria-floribunda-agglutinin-and-its-reactive-glycan-carrying-prostate-specific-antigen-as-a-novel-diagnostic-and-prognostic-marker-of-prostate-cancer
#17
Kazuhisa Hagiwara, Yuki Tobisawa, Takatoshi Kaya, Tomonori Kaneko, Shingo Hatakeyama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Yoshihiko Suda, Chikara Ohyama, Tohru Yoneyama
Wisteria floribunda agglutinin (WFA) preferably binds to LacdiNAc glycans, and its reactivity is associated with tumor progression. The aim of this study to examine whether the serum LacdiNAc carrying prostate-specific antigen-glycosylation isomer (PSA-Gi) and WFA-reactivity of tumor tissue can be applied as a diagnostic and prognostic marker of prostate cancer (PCa). Between 2007 and 2016, serum PSA-Gi levels before prostate biopsy (Pbx) were measured in 184 biopsy-proven benign prostatic hyperplasia patients and 244 PCa patients using an automated lectin-antibody immunoassay...
January 26, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28127114/cacna1b-cav2-2-overexpression-and-its-association-with-clinicopathologic-characteristics-and-unfavorable-prognosis-in-non-small-cell-lung-cancer
#18
Xiaoyu Zhou, Wei Wang, Shu Zhang, Xudong Wang, Zhiyuan Tang, Jun Gu, Jun Li, Jianan Huang
CACNA1B (Cav2.2) encodes an N-type voltage-gated calcium channel (VGCC) ubiquitously expressed in brain and peripheral nervous system that is important for regulating neuropathic pain. Because intracellular calcium concentration is a key player in cell proliferation and apoptosis, VGCCs are implicated in tumorigenesis. Recent studies have identified CACNA1B (Cav2.2) being overexpressed in prostate and breast cancer tissues when compared to adjacent normal tissues; however, its role in non-small cell lung cancer (NSCLC) has not been investigated...
2017: Disease Markers
https://www.readbyqxmd.com/read/28123630/set-and-mynd-domain-containing-protein-3-in-cancer
#19
REVIEW
Lei Huang, A-Man Xu
Lysine methylation plays a vital role in histone modification. Deregulations of lysine methyltransferases and demethylases have been frequently observed in human cancers. The SET and MYND domain containing protein 3 (SMYD3) is a novel histone lysine methyltransferase and it functions by regulating chromatin during the development of myocardial and skeletal muscle. It has been recently unveiled to play significant roles in human cancer genesis and progression via regulating various key cancer-associated genes and pathways and promoting cell proliferation and migration...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28122723/male-breast-cancer-a-single-institution-clinicopathologic-and-immunohistochemical-study
#20
Kate M Serdy, José Pablo Leone, David J Dabbs, Rohit Bhargava
OBJECTIVES: A clinicopathologic study with an emphasis on tumor immunohistochemical profile is presented. METHODS: Sixty-one cases of male invasive breast cancers were studied. Median age of the cohort was 65 years. RESULTS: Ninety-seven percent were estrogen receptor positive+ and 10% human epidermal growth factor receptor 2 positive. The individual diagnostic marker positivity was 98% for GATA-binding protein 3, 95% for androgen receptor, 90% for progesterone receptor, 88% for deleted in pancreatic cancer 4, 75% for gross cystic disease fluid protein 15, 72% for cytokeratin 7, 55% for mammaglobin, and 15% for vimentin and Wilms tumor protein 1...
January 24, 2017: American Journal of Clinical Pathology
keyword
keyword
98461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"